Tuesday, April 12, 2016

These are the 50 most dangerous drugs on the market

While overdose deaths from prescription opioids have nearly quadrupled since 1999, some of the most dangerous drugs don’t require a prescription.
Using data from the Food and Drug Administration for 2004 through 2015, HealthGrove looked at the 150 drugs that are involved in the highest number of adverse reactions and ranked them by the percent of these reactions classified as serious. For many of these reactions, the FDA database uses medical terminology, such as pyrexia and dyspnoea for fever and labored breathing, respectively.
The top 50 drugs with the most serious adverse reactions are considered the most dangerous. Though most on the list require a prescription and treat serious diseases, those like Advil andacetaminophen don’t.
It’s important to note that these medicines may not be inherently dangerous, but improper dosage, combining medicines or taking them with substances like alcohol can dramatically increase risk.
One-third of Americans say they “combine medications when treating multiple symptoms,” according to the National Council on Patient Information, cited in a New York Times report on over-the-counter medicines. The same source also claims that only one in ten people read the labels entirely and one in five admits to using medication more than the label indicates. This creates an environment primed for unintended drug interactions and overdoses.
Additionally, people over 65 years old — those most likely to take multiple drugs for chronic health issues — account for approximately 40 percent of over-the-counter drug usage. This puts this group at greater risk for trouble with these drugs by way of adverse side effects and interactions.
Despite the potential for negative consequences of drug use and misuse, modern pharmaceuticals have greatly contributed to the health and longevity of people around the world. Though many are regarded as safe, as more drugs become available over the counter and prescriptions of others rise, consumer awareness becomes increasingly important.
Note: In the case of ties, the drug with the highest number of total reported reactions is ranked higher.

#50. Losartan

Percent of Reactions That Were Serious: 70%
Number of Serious Reactions: 24,242
Total Number of Reported Reactions: 34,571
Therapeutic Class: Cardiovascular Agent
Brand Names: Cozaar

#49. Alprazolam

Percent of Reactions That Were Serious: 70%
Number of Serious Reactions: 51,950
Total Number of Reported Reactions: 73,606
Therapeutic Class: Antianxiety
Brand Names: Gabazolamine-0.5, Niravam, Xanax, Xanax Xr, Alti-Alprazolam

#48. Tramadol

Percent of Reactions That Were Serious: 71%
Number of Serious Reactions: 26,278
Total Number of Reported Reactions: 36,867
Therapeutic Class: Analgesic
Brand Names: Conzip, Fusepaq Synapryn, Rybix Odt, Ryzolt, Ultram, Ultram Er

#47. Venlafaxine

Percent of Reactions That Were Serious: 71%
Number of Serious Reactions: 33,623
Total Number of Reported Reactions: 47,132
Therapeutic Class: Antidepressant
Brand Names: Effexor, Effexor-Xr

#46. Sertraline

Percent of Reactions That Were Serious: 71%
Number of Serious Reactions: 45,622
Total Number of Reported Reactions: 64,182
Therapeutic Class: Antidepressant
Brand Names: Zoloft

#45. Metoprolol

Percent of Reactions That Were Serious: 71%
Number of Serious Reactions: 71,979
Total Number of Reported Reactions: 100,829
Therapeutic Class: Cardiovascular Agent
Brand Names: Lopressor, Toprol Xl

#44. Aspirin

Percent of Reactions That Were Serious: 71%
Number of Serious Reactions: 134,402
Total Number of Reported Reactions: 187,836
Therapeutic Class: Analgesic
Brand Names: Ascriptin, Aspergum, Aspirtab, Bayer, Easprin, Ecotrin, Ecpirin, Entercote, Genacote, Halfprin, Ninoprin, Norwich Aspirin

#43. Atenolol

Percent of Reactions That Were Serious: 72%
Number of Serious Reactions: 45,374
Total Number of Reported Reactions: 62,930
Therapeutic Class: Cardiovascular Agent
Brand Names: Tenormin

#42. Prednisone

Percent of Reactions That Were Serious: 72%
Number of Serious Reactions: 60,187
Total Number of Reported Reactions: 83,321
Therapeutic Class: Endocrine-Metabolic Agent
Brand Names: Deltasone, Prednicot, Prednisone Intensol, Rayos, Sterapred, Sterapred Ds

#41. Fluoxetine

Percent of Reactions That Were Serious: 73%
Number of Serious Reactions: 36,722
Total Number of Reported Reactions: 50,213
Therapeutic Class: Antidepressant
Brand Names: Prozac, Prozac Weekly, Rapiflux, Sarafem, Selfemra, Phl-Fluoxetine

#40. Fentanyl

Percent of Reactions That Were Serious: 74%
Number of Serious Reactions: 29,996
Total Number of Reported Reactions: 40,444
Therapeutic Class: Analgesic
Brand Names: Abstral, Actiq, Fentora, Onsolis, Subsys

#39. Acetaminophen

Percent of Reactions That Were Serious: 74%
Number of Serious Reactions: 119,389
Total Number of Reported Reactions: 160,481
Therapeutic Class: Analgesic
Brand Names: Ofirmev

#38. Amlodipine

Percent of Reactions That Were Serious: 75%
Number of Serious Reactions: 95,694
Total Number of Reported Reactions: 126,505
Therapeutic Class: Cardiovascular Agent
Brand Names: Norvasc

#37. Cyclosporine

Percent of Reactions That Were Serious: 76%
Number of Serious Reactions: 24,422
Total Number of Reported Reactions: 31,881
Therapeutic Class: Immune Suppressant
Brand Names: Gengraf, Neoral, Sandimmune, Apo-Cyclosporine

#36. Risperidone

Percent of Reactions That Were Serious: 76%
Number of Serious Reactions: 34,023
Total Number of Reported Reactions: 44,415
Therapeutic Class: Antipsychotic
Brand Names: Risperdal, Risperdal M-Tab, Risperidone M-Tab

#35. Warfarin

Percent of Reactions That Were Serious: 76%
Number of Serious Reactions: 79,961
Total Number of Reported Reactions: 104,230
Therapeutic Class: Anticoagulant
Brand Names: Coumadin, Jantoven

#34. Lorazepam

Percent of Reactions That Were Serious: 77%
Number of Serious Reactions: 42,737
Total Number of Reported Reactions: 54,873
Therapeutic Class: Antianxiety
Brand Names: Ativan, Lorazepam Intensol

#33. Valsartan

Percent of Reactions That Were Serious: 77%
Number of Serious Reactions: 46,987
Total Number of Reported Reactions: 60,639
Therapeutic Class: Cardiovascular Agent
Brand Names: Diovan

#32. Pantoprazole

Percent of Reactions That Were Serious: 77%
Number of Serious Reactions: 48,736
Total Number of Reported Reactions: 62,968
Therapeutic Class: Gastric Acid Secretion Inhibitor
Brand Names: Protonix, Protonix Iv

#31. Oxycodone

Percent of Reactions That Were Serious: 77%
Number of Serious Reactions: 56,165
Total Number of Reported Reactions: 72,020
Therapeutic Class: Analgesic
Brand Names: Dazidox, Eth-Oxydose, Oxaydo, Oxycontin, Oxycontin Cr, Oxydose, Oxyfast, Oxy Ir, Roxicodone, Roxicodone Intensol, Apo-Oxycodone Cr, Co Oxycodone Cr, Oxycodone, Oxy-Ir, Oxyneo, Pms-Oxycodone

#30. Drospirenone And Ethinyl Estradiol

Percent of Reactions That Were Serious: 78%
Number of Serious Reactions: 31,921
Total Number of Reported Reactions: 40,426
Therapeutic Class: Monophasic Contraceptive Combination
Brand Names: Gianvi, Loryna, Nikki, Ocella, Syeda, Vestura, Yasmin, Yaz, Yaz 28, Zarah

#29. Citalopram

Percent of Reactions That Were Serious: 78%
Number of Serious Reactions: 42,147
Total Number of Reported Reactions: 53,752
Therapeutic Class: Antidepressant
Brand Names: Celexa

#28. Diclofenac

Percent of Reactions That Were Serious: 79%
Number of Serious Reactions: 27,921
Total Number of Reported Reactions: 35,286
Therapeutic Class: Central Nervous System Agent
Brand Names: Cambia, Cataflam, Voltaren, Voltaren-Xr, Zipsor, Zorvolex

#27. Conjugated Estrogens

Percent of Reactions That Were Serious: 79%
Number of Serious Reactions: 40,659
Total Number of Reported Reactions: 51,272
Therapeutic Class: Female Reproductive Agent
Brand Names: Premarin, Premarin Vaginal

#26. Olanzapine

Percent of Reactions That Were Serious: 80%
Number of Serious Reactions: 32,222
Total Number of Reported Reactions: 39,957
Therapeutic Class: Antipsychotic
Brand Names: Zyprexa, Zyprexa Zydis

#25. Diazepam

Percent of Reactions That Were Serious: 81%
Number of Serious Reactions: 31,794
Total Number of Reported Reactions: 38,978
Therapeutic Class: Anticonvulsant
Brand Names: Diastat, Diastat Pediatric

#24. Rivaroxaban

Percent of Reactions That Were Serious: 81%
Number of Serious Reactions: 33,317
Total Number of Reported Reactions: 41,114
Therapeutic Class: Anticoagulant
Brand Names: Xarelto

#23. Alendronate

Percent of Reactions That Were Serious: 82%
Number of Serious Reactions: 39,257
Total Number of Reported Reactions: 47,769
Therapeutic Class: Calcium Regulator
Brand Names: Fosamax

#22. Clopidogrel

Percent of Reactions That Were Serious: 82%
Number of Serious Reactions: 70,205
Total Number of Reported Reactions: 85,447
Therapeutic Class: Platelet Aggregation Inhibitor
Brand Names: Plavix

#21. Furosemide

Percent of Reactions That Were Serious: 82%
Number of Serious Reactions: 102,865
Total Number of Reported Reactions: 124,020
Therapeutic Class: Cardiovascular Agent
Brand Names: Furocot, Lasix

#20. Digoxin

Percent of Reactions That Were Serious: 83%
Number of Serious Reactions: 30,355
Total Number of Reported Reactions: 36,506
Therapeutic Class: Cardiovascular Agent
Brand Names: Digitek, Digox, Lanoxicaps, Lanoxin, Lanoxin Pediatric, Digitaline Nativelle

#19. Spironolactone

Percent of Reactions That Were Serious: 84%
Number of Serious Reactions: 28,871
Total Number of Reported Reactions: 34,336
Therapeutic Class: Cardiovascular Agent
Brand Names: Aldactone

#18. Allopurinol

 
Percent of Reactions That Were Serious: 84%
Number of Serious Reactions: 30,921
Total Number of Reported Reactions: 36,755
Therapeutic Class: Antigout
Brand Names: Aloprim

#17. Morphine

Percent of Reactions That Were Serious: 84%
Number of Serious Reactions: 37,986
Total Number of Reported Reactions: 44,906
Therapeutic Class: Analgesic
Brand Names: Avinza, Kadian, Kadian Er, Morphabond, Ms Contin, Msir, Oramorph Sr, Roxanol, Roxanol-T

#16. Ondansetron

Percent of Reactions That Were Serious: 85%
Number of Serious Reactions: 31,005
Total Number of Reported Reactions: 36,133
Therapeutic Class: Antiemetic
Brand Names: Zofran, Zofran Odt, Zuplenz

#15. Ramipril

Percent of Reactions That Were Serious: 85%
Number of Serious Reactions: 32,374
Total Number of Reported Reactions: 37,895
Therapeutic Class: Antihypertensive
Brand Names: Altace

#14. Rosiglitazone

Percent of Reactions That Were Serious: 85%
Number of Serious Reactions: 87,352
Total Number of Reported Reactions: 101,873
Therapeutic Class: Antidiabetic
Brand Names: Avandia

#13. Medroxyprogesterone

Percent of Reactions That Were Serious: 89%
Number of Serious Reactions: 34,018
Total Number of Reported Reactions: 38,079
Therapeutic Class: Endocrine-Metabolic Agent
Brand Names: Provera, Alti-Mpa

#12. Lenalidomide

Percent of Reactions That Were Serious: 89%
Number of Serious Reactions: 69,123
Total Number of Reported Reactions: 77,417
Therapeutic Class: Immune Modulator
Brand Names: Revlimid

#11. Methylprednisolone

Percent of Reactions That Were Serious: 90%
Number of Serious Reactions: 30,040
Total Number of Reported Reactions: 33,095
Therapeutic Class: Endocrine-Metabolic Agent
Brand Names: Medrol, Medrol Dosepak, Methylpred-Dp

#10. Metoclopramide

Percent of Reactions That Were Serious: 91%
Number of Serious Reactions: 32,757
Total Number of Reported Reactions: 35,623
Therapeutic Class: Antiemetic
Brand Names: Metozolv Odt, Reglan

#9. Infliximab

Percent of Reactions That Were Serious: 91%
Number of Serious Reactions: 68,167
Total Number of Reported Reactions: 74,738
Therapeutic Class: Immunological Agent
Brand Names: Remicade

#8. Tacrolimus

Percent of Reactions That Were Serious: 92%
Number of Serious Reactions: 27,964
Total Number of Reported Reactions: 30,262
Therapeutic Class: Antipsoriatic
Brand Names: Protopic

#7. Zoledronic Acid

Percent of Reactions That Were Serious: 93%
Number of Serious Reactions: 35,581
Total Number of Reported Reactions: 38,016
Therapeutic Class: Calcium Regulator
Brand Names: Reclast, Zometa

#6. Dexamethasone

Percent of Reactions That Were Serious: 93%
Number of Serious Reactions: 38,966
Total Number of Reported Reactions: 41,636
Therapeutic Class: Endocrine-Metabolic Agent
Brand Names: Baycadron Elixer, Decadron, Dekpak 13 Day Taperpak, Dexamethasone Intensol, Dexpak, Dexpak 10 Day Taperpak, Dexpak Jr, Zema-Pak

#5. Clozapine

Percent of Reactions That Were Serious: 95%
Number of Serious Reactions: 29,470
Total Number of Reported Reactions: 30,914
Therapeutic Class: Antipsychotic
Brand Names: Clozaril, Fazaclo, Versacloz

#4. Rituximab

Percent of Reactions That Were Serious: 96%
Number of Serious Reactions: 30,014
Total Number of Reported Reactions: 31,157
Therapeutic Class: Antineoplastic Agent
Brand Names: Rituxan

#3. Bevacizumab

Percent of Reactions That Were Serious: 96%
Number of Serious Reactions: 39,957
Total Number of Reported Reactions: 41,281
Therapeutic Class: Immunological Agent
Brand Names: Avastin

#2. Prednisolone

Percent of Reactions That Were Serious: 96%
Number of Serious Reactions: 42,323
Total Number of Reported Reactions: 43,817
Therapeutic Class: Endocrine-Metabolic Agent
Brand Names: Bubbli-Pred, Cotolone, Flo-Pred, Millipred, Millipred Dp, Orapred, Orapred Odt, Pediapred, Prelone, Veripred 20, Pms-Prednisolone

#1. Cyclophosphamide

Percent of Reactions That Were Serious: 97%
Number of Serious Reactions: 33,128
Total Number of Reported Reactions: 34,076
Therapeutic Class: Antineoplastic Agent
Brand Names: Cytoxan, Cytoxan Lyophilized
SOURCE: Sabrina Perry| POSTED&UPDATED - 1:23 PM, Apr 11, 2016LINK - http://www.nbc26.com/news/national/these-are-the-50-most-dangerous-drugs-on-the-market

Federal reclassification of marijuana could expand medical uses

WASHINGTON - Federal authorities have announced that they are reviewing the possibility of loosening the classification of marijuana, and if this happens, it could have a far-reaching impact on how the substance is used in medical settings, experts said.
Marijuana is currently classified as a Schedule I drug, meaning it is listed alongside heroin and LSD as among the "most dangerous drugs" and has "no currently accepted medical use and a high potential for abuse."
The Drug Enforcement Agency announced last week that it is reviewing the possibility of reclassifying it as a Schedule II drug, which would put it in the same category as Ritalin, Adderal and oxycodone.
Medical experts are welcoming the review, saying it could ease restrictions for researchers, so that they can better understand which compounds in marijuana could be used to help patients.
The American Medical Association told ABC News that the group supports the review "to help facilitate scientific research and the development of cannabinoid-based medicines."
"The Drug Enforcement Administration should work with other federal regulatory agencies to develop a special schedule for marijuana to facilitate study of its potential medical utility in prescription drug products," AMA officials told ABC News in a statement.
"Current standards for approval of prescription drug products require rigorous scientific study. While studies related to a limited number of medical conditions have shown promise for new cannabinoid-based prescription products, the scope of rigorous research needs to be expanded to a broader range of medical conditions for such products," the AMA added.
Dr. Kevin Hill, assistant professor of psychiatry at McLean Hospital and Harvard Medical School, published a review of medical marijuana in the Journal of the American Medical Association in 2015. In that review, he emphasized there are significant barriers for researchers who want to study marijuana for its medicinal potential.
There are "hoops you have to run through for this research," Hill told ABC News. "If you use marijuana itself, you have to get special licensing from the DEA. It involves a background visit and ... they don’t give it out very easily."
There are currently two marijuana-derived medications approved by the U.S. Food and Drug Administration, Hill noted. The active ingredients in both medications are a group of compounds known as cannabinoids, and these chemicals are approved for nerve pain and for stimulating appetite in patients undergoing cancer treatment, Hill said. However, many other people use medical marijuana or marijuana-derived compounds for a host of other conditions from epilepsy to vertigo, he said.
"We know that medical marijuana has good evidence for treatment for a handful of medical conditions," Hill said. "There are thousands of people who are using medical marijuana for a whole host of medical conditions," where the efficacy has yet to be thoroughly studied.
By changing the classification of the drug, Hill said researchers and doctors could find out how effective marijuana is in other conditions.
"We could move toward a more evidence-based use of medical marijuana," Hill said.
Hill pointed out there are around 60 known compounds in marijuana and that many have not been thoroughly studied by researchers looking for medicinal uses. A new classification will mean it will be easier for researchers to obtain licenses to examine these chemicals for medical treatments and to access suppliers, experts said.
Steph Sherer, the founder of the medical marijuana advocacy group Americans for Safe Access, said changing the classification could be a "paradigm change." She pointed out there is currently only one supplier of medical marijuana for researchers.
"It will allow more federal institutions to engage in research and allow the NIDA [National Institute on Drug Abuse] to open up its source for cannabis so there’s not just one place for researchers to use" marijuana, she explained.
The DEA along with the U.S. Department of Health and Human Services and Office of National Drug Control Policy announced they would review marijuana's classification after multiple letters from senators last year, including Sen. Elizabeth Warren, D-Massachusetts, and Sen. Kirsten Gillibrand, D-New York.
"For too long schedule I status for marijuana has been a barrier for necessary research, and as a result countless Americans can't get access to medicine they desperately need," Gillibrand said in a statement last week. "It's past due for the DEA to reconsider marijuana's status. I am hopeful that antiquated ideology won't continue to stand in the way of science and that the DEA will reschedule marijuana to schedule II."
SOURCE: Gillian Mohney, ABC News , KVUE , WTSP 7:41 PM. EST April 11, 2016 LINK - http://www.wtsp.com/news/health/federal-reclassification-of-marijuana-could-expand-medical-uses/128758731

Monday, March 28, 2016

Pop a pill – Career in Pharmacy

pharmacy

With healthcare becoming essential and popular by the day, the field of pharmacy offers great career options as well

Sector overview

As per a report by Equity Master, the Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value. According to reports, globally, our country is the largest provider of generic drugs. Indian drugs are exported to over 200 nations across the globe, including many developed countries, and the United States being one of the major importers. With that and other drugs, India holds quite an important position in the worldwide pharmaceuticals sector, and it is expected to expand even further in the coming years. India also has a large pool of educated and trained scientists, and engineers within the sector who drive it higher.
With that, as aspirant can understand that the sector in India is very dynamic and has opportunities for all those who are interested and trained. It has a lot to offer within the domestic as well as the international markets. All the trade reports peg at the industry growing well, and with a growing industry, there will be job options as well. With the government initiatives and private sector investments providing impetus to this industry, the path ahead seems to be one of growth.
In the next five years, it is expected that India will be among the top three pharmaceutical markets in the world. One of the reasons for this incremental growth is also that the cost of production in India is much lower than that of other markets like the US or Europe. This factor provides quite a steep competitive edge to India.
Any aspirant, who thinks of entering this field, will have a career charted out with growth and success, according to many practitioners in the field.

To get there

To enter this field, the path is linear and simple. To opt for the bachelor’s degree, an aspirant needs to take up science after class 12 (HSC or equivalent) with the subject combination of physics, chemistry, biology and maths. The four-year undergraduate programme leads to the bachelor’s degree – the BPharm. There are master’s programmes also offered to those who have completed their BPharm. There are specialisation options available with the master’s programme which will also pave the way for a doctoral programme for those who are interested in specific research via a PhD.
The other option for a student is to take up a diploma after completing class 12, but the options after a diploma might be limited in nature since it is a less comprehensive programme compared to the degree option.
There are other inter-disciplinary options as well like pharma management, or pharmacy and technology.
Some institutes in Mumbai include:
  • Institute of Chemical Technology, Matunga
  • Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle
  • MET Institute of Pharmacy, Bandra
  • Principal K. M. Kundnani College of Pharmacy, Cuffe Parade
  • Vivekanand Education Society’s College of Pharmacy, Chembur
  • SNDT’s C. U. Shah College of Pharmacy, Juhu
  • Dr. L. H. Hiranandani College of Pharmacy, Thane
  • Bombay College of Pharmacy, Kalina
  • H.K. College of Pharmacy, Jogeshwari
  • Bharati Vidyapeeth’s College of Pharmacy, Belapur
  • Garware Institute of Career Education and Development (GICED), Santacruz
  • SNDT’S Premlila Vithaldas Polytechnic (PVP Mumbai), Juhu

A student says

Mayur Pawar, Pursuing his prorgamme
 Medical sciences advances are necessary in a country like ours which is faced with a multitude of medical problems. These need to be dealt with at several levels, and for that, medicines are needed. Medicines today are becoming more complex as drugs are advancing and becoming extremely specific.  In college, we learn from a variety of subjects and cases, and training provides us with the necessary skills to work in this field as well. Apart from gaining scientific knowledge, students develop several skills over the four year bachelor’s programme, which enable them to work in the industry in future. These include critical and rational thinking, problem solving, evaluation of research and teamwork.
Those who work in this profession are called pharmacists and they need to learn about the composition of various drugs, and their chemical and physical properties and also their uses. They also need to learn the effects of the various drugs on people’s health, including the side effects as well. We also need to understand the procedures for testing the purity of the drugs and their strength. If you have the physical strength to pursue this course, go for it keeping in mind that it is a rigorous course and needs a lot of effort and dedication, besides a scientific temperament which is a must.

Market and remuneration

This is a field where specialised knowledge is necessary for any job role. A lot of people who think in the old school fashion still believe that pharmacy is a career option only second to medicine, but this industry has proved its own mettle, and has professionals who are doing very well. Pharmacists apply their specialized knowledge and skill to determine drug treatment plans, monitor responses to drug therapy, and recommend treatment alternatives.
A wide range of career opportunities can be found in this field. Job descriptions exist in production of drugs, research and development, scientists, production manager, dispensing pharmacists and perhaps as a medical representative in sales and marketing. Those who have completed their master’s degree or even a PhD, will have options in teaching as well.
Since this industry is highly driven by research and development, most pharmacy graduates look for projects where they can work in the areas of developing, manufacturing, marketing and monitoring medicines. The area a person works in will depend on the field one chooses. Many institutions offer campus placements after a bachelor’s degree, and the stream of work gets automatically chosen for students who opt for these placements.
The salaries offered in this sector reflect the growth in it, as it is a well-paying field. The initial pay depends on the job description, as well as the employing organisation, and the institute the candidate has pursued a course in.
For fresh graduates who have completed their BPharm from a reputed institute and are perhaps placed on campus, starting salaries range from Rs. 3.5 lakh per annum at the minimum going up to Rs. 4.5 lakh. With experience the salaries rise.

An aspirant asks

Kshama Joshi, SSC student 
I am interested in the field of pharmacy, and I have my family’s backing in terms of helping me to set up a drug store in future if I want it. But I am afraid that I might not be able to do well enough if I opt for this programme because I am very bad at rote learning, and I am sure this field needs a person to learn the drugs and its properties by rote. Also, if I want to work in research, is a master’s degree compulsory?
Our professional answers: If you have done well until now within the Indian education system, I see no reason why you cannot do well in a BPharm programme as well. In this programme, not much rote learning it needed, since there are projects and scientific papers and evaluations as well. You may have to learn a little bit during the exams, but that I think any person who is interested in the field, like yourself, will be able to manage. You will need to know the basics that you will keep applying to the assignments, but once you get used to the basics, you will enjoy it. For a job in research, although a master’s will be really helpful and fast track your career, it is not compulsory. You will be able to pursue research even with a bachelor’s degree if you mould yourself in that route during your undergraduate studies. Your professors may also be able to guide you for that.